



## ASX Announcement

4 July 2019

### Elixinol signs exclusive distribution agreement for German pharmacy channels

**Elixinol Global Limited (Elixinol Global or the Company) (ASX:EXL; OTCQX:ELLXF)** is pleased to announce that its Dutch based wholly-owned subsidiary, Elixinol BV (**Elixinol**), has signed an exclusive distribution agreement with MedVec International GmbH (**Distributor**) for pharmacy and para pharmacy channels in Germany.

Under the terms of the exclusive distribution agreement, the Distributor will sell Elixinol branded products and white label products via its existing sales network in the pharmacy and para pharmacy sector for an initial graduated period and provides for an extension for a further three years.

The exclusivity of the distribution agreement is based on achievement of minimum annual sales targets. Should the sales targets not be met the distribution agreement will become co-exclusive. In addition, the Distributor will be appointed co-exclusive for pharmacy and para pharmacy channels in Austria and Switzerland.

This distribution agreement builds on the initiatives Elixinol Global announced 5 February 2019 with expansion of European operations to leverage the significant opportunity within the European hemp and cannabis market.

Elixinol Global Chief Executive Officer, Mr Paul Benhaim, said: *“The distribution agreement with MedVec allows Elixinol to significantly expand its presence in Germany, the largest pharmacy market in Europe, as well as Austria and Switzerland.”*

MedVec International founder, Mr Knut Butzinger, said: *“We are excited to partner with Elixinol for the exclusive distribution of Elixinol branded and white label products and leverage our valuable pharmacy distribution channels in Europe. We believe our experienced sales team and market reach to over 15,000 pharmacies in Germany will deliver strong market results for Elixinol.”*

For more information please contact:

Ron Dufficy

Chief Financial Officer

[ron.dufficy@elixinolglobal.com](mailto:ron.dufficy@elixinolglobal.com)



### **About Elixinol Global**

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) is a global leader in the cannabis industry, selling hemp-derived CBD dietary supplements, hemp food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products.

Elixinol Global's businesses include:

- Elixinol LLC (Elixinol), a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA;
- Hemp Foods Australia Pty Ltd (Hemp Foods Australia), a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products; and
- Nunyara Pharma Pty Ltd (Nunyara), founded in 2014 to participate in the emerging Australian medicinal cannabis market. Nunyara submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.

See more at [www.elixinolglobal.com](http://www.elixinolglobal.com)

### **About MedVec International**

MedVec provides a full spectrum of sales, marketing and logistics for MedVec-branded or licensed rapid/POC diagnostics and complementary products to pharmacies, allied health practitioners, labs, hospitals and doctors.

MedVec markets products via a nationwide sales team and has achieved a leading position for its products in Germany's pharmacies. Our pharmacy sales team consists of 30+ staff members and has about 15,000 active pharmacy accounts in Germany.

See more at [www.medvec.com](http://www.medvec.com)